AbbVie Inc at Piper Sandler Healthcare Conference Transcript
All right. Good morning, everyone. Day 2 at the 37th Annual Piper Sandler Healthcare Conference. And we're delighted to have the team from AbbVie with us. This is David Amsellem from the Piper Sandler Biopharma team.
So we have Roopal Thakkar, Head of R&D. We have Scott Reents, CFO. We have Jeff Stewart, Chief Commercial Officer. Certainly lots to talk about.
Questions & Answers
I wanted to kick things off with a high-level question, and I'll try to ignore the construction. So at a high level, I would say within biotech this year, we've seen the best of times. We've seen the worst of times. What we're also seeing more recently is an uptick in M&A activity. So it kind of leads me to a question about how AbbVie is thinking about capital deployment.
Where does the company stand regarding its motivation to do larger scale transactions along the lines of, say, ImmunoGen a few years back? Or is the focus going to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
